Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail
It seems that Illumina (NASDAQ: ILMN) is making a push into the cancer diagnostics space. According to an article published Wednesday by Reuters citing "people familiar with the matter," the gene-sequencing specialist is in discussions to purchase Grail -- an early-stage company active in the segment.
While privately held, Grail would make a pricey target. According to Reuters' sources, after several funding rounds, it's valued at around $6 billion.
Image source: Getty Images.
Source Fool.com
